146,596 Shares in Lion Biotechnologies, Inc. (IOVA) Purchased by Teachers Advisors LLC

Teachers Advisors LLC acquired a new stake in Lion Biotechnologies, Inc. (NASDAQ:IOVA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 146,596 shares of the biotechnology company’s stock, valued at approximately $1,077,000. Teachers Advisors LLC owned 0.24% of Lion Biotechnologies as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in IOVA. Franklin Resources Inc. purchased a new position in shares of Lion Biotechnologies during the second quarter valued at approximately $37,844,000. Victory Capital Management Inc. purchased a new position in shares of Lion Biotechnologies during the second quarter valued at approximately $19,013,000. JPMorgan Chase & Co. purchased a new position in shares of Lion Biotechnologies during the second quarter valued at approximately $8,006,000. AXA purchased a new position in shares of Lion Biotechnologies during the second quarter valued at approximately $4,989,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Lion Biotechnologies during the second quarter valued at approximately $1,796,000. 66.64% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “146,596 Shares in Lion Biotechnologies, Inc. (IOVA) Purchased by Teachers Advisors LLC” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://stocknewstimes.com/2017/11/11/teachers-advisors-llc-purchases-shares-of-146596-lion-biotechnologies-inc-iova.html.

Shares of Lion Biotechnologies, Inc. (NASDAQ IOVA) traded up $0.20 on Friday, hitting $8.05. The company’s stock had a trading volume of 517,300 shares, compared to its average volume of 363,658. Lion Biotechnologies, Inc. has a 52-week low of $4.45 and a 52-week high of $8.60.

Lion Biotechnologies (NASDAQ:IOVA) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). equities research analysts predict that Lion Biotechnologies, Inc. will post -1.37 EPS for the current year.

IOVA has been the topic of several analyst reports. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $13.00 target price on shares of Lion Biotechnologies in a research report on Tuesday, September 26th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Lion Biotechnologies in a report on Wednesday, September 13th. Chardan Capital reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and set a $11.00 price target on shares of Lion Biotechnologies in a report on Tuesday, September 5th. Finally, Cowen and Company reiterated a “buy” rating on shares of Lion Biotechnologies in a report on Wednesday, August 16th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $14.53.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Institutional Ownership by Quarter for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply